|
SocialPicks Sentiment:
N/A
** not enough data to be rated
|
This Quarter's Sentiment:
|
|
|
From the Blogosphere
Another Win for Mylan – Analyst Blog
|
|
|
Recently, Mylan Inc.‘s (MYL) subsidiary, Matrix Laboratories received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Lansoprazole Delayed-release (DR) capsules in two dosage forms (15 mg and 30 mg). Mylan plans to begin shipment of the product immediately.
The drug is the generic version of Takeda Pharmaceuticals' (TKPHY.PK) proton pump inhibitor Prevacid DR Capsules. According to IMS Health (RX), the branded version had US sales of approximately $3 billion for the 12 months ending June 30.
Mylan received quite a few app...
|
AstraZeneca Beats, Raises – Analyst Blog
|
|
|
AstraZeneca’s (AZN) third quarter earnings came in at $1.68 per American Depositary Shares (ADS), well above the Zacks Consensus Estimate of $1.36 and $1.32 reported in the year-ago period. Revenues increased 10% at constant exchange rates (CER) to $8.2 billion compared to the same period last year.
The primary reasons for the increase in revenues were strong US sales of Toprol-XL benefiting from generic withdrawal, US sales of its H1N1 vaccine and robust growth in emerging markets.
AstraZeneca recorded strong sales across all geographies. Sales in North America, Emerging Markets and Estab...
|
CTIC Reports, Awaiting FDA Decision – Analyst Blog
|
|
|
Cell Therapeutics’ (CTIC) third quarter loss per share came in at 8 cents compared to a loss of $1.14 reported in the year ago period. The company does not have any marketed product at present; it derives revenues primarily in the form of license and contract revenues. Cell Therapeutics recorded revenues of $0.02 million compared to $2.6 million in the third quarter of 2009.
Revenues in the year ago period consisted of product sales of Zevalin, which the company sold to Spectrum Pharmaceuticals earlier in 2009. Operating expenses during the quarter increased 32.5% to $27 million primaril...
|
Isis Loss Widens – Analyst Blog
|
|
|
Isis Pharmaceuticals Inc. (ISIS) reported a net loss of 7 cents per share in the third quarter, which was wider than the Zacks Consensus Estimate of a net loss of 5 cents. The company had reported a net income of 2 cents in the year ago period. The wider-than-expected loss was due to lower revenues and higher operating expenses.
Revenues declined 9.1% to $26.8 million. Revenues include license fees, milestone-related payments and other payments. Revenues declined during the reported quarter as the company finished amortizing the revenue associated with the $50 million upfront payment recei...
|
King Beats, but Earnings Down – Analyst Blog
|
|
|
King Pharmaceuticals, Inc. (KG) reported third quarter earnings of 29 cents per share, beating the Zacks Consensus Estimate by 2 cents. Despite revenues increasing 19.3% from the year-ago period, earnings declined 25.6% from the year-ago quarter mainly due to higher operating expenses.
Total revenues came in at $463.3 million. The primary growth drivers were the Animal Health business, which came as a part of the Alpharma acquisition and an increase in sales of auto-injectors in the Meridian business.
King’s branded pharmaceuticals segment posted revenues of $283 million, down 6.3% from the p< />< /><><><><>< />< /><>< />< />< />< />< />< />< />< />< />< /><><>< /><>< /><>< /><>< /><>< /><>< /><>< /><><>< /><>< /><>< />< />...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About N 2009 Apr 18 5.00 Call
- Answers.com
